Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Healthcare · NSE: DRREDDY · BSE: 500124

Dr. Reddy's: how the business works

Dr. Reddy's makes generic and branded medicines and their ingredients, and sells them in 87 countries; FY26 revenue was ₹33,700 crore.

Follow Dr. Reddy's

Email me when Dr. Reddy's's page is updated after results.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

Dr. Reddy's Laboratories Limited · Hyderabad, Telangana · Founded 1984

Updated for Q2 FY27 · checked

Revenue, FY26
₹33,700 cr
Profit to shareholders, FY26
₹4,196 cr
Countries it sells in, FY26
87
Permanent employees, FY26
27,527
Promoter holding, Sep 2026 (none pledged)
26.63%

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Dr. Reddy's in 5 points

  1. 1 · What it sells

    The company makes generic and branded medicines and the active ingredients that go into them, and its FY26 revenue from operations was ₹33,700 crore.

    More: what it sells

  2. 2 · Who pays it

    In FY26, customers in the US paid 35.1% of the company's revenue, customers in India 19.2%, Russia 10.4% and all other countries 35.3%.

    More: who pays it

  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, including ₹1,358 crore of other income, the company kept ₹12.0 as profit for shareholders, and its operating EBITDA margin on revenue was 19.1% (Cityfort calculation, after ₹352 crore of write-downs).

    More: what it keeps from ₹100

  4. 4 · Where the operating profit comes from

    Global Generics earned ₹16,970 crore of the company's ₹17,728 crore FY26 gross profit, while active ingredients and services (PSAI) earned ₹600 crore.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    US lenalidomide exclusivity ended in Jan 2026, and the company's North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier by its own count.

    More: the one thing to watch

Sources: From Dr. Reddy's FY26 annual report, its Q4 FY26 and Q2 FY27 results filings and presentation, and ICRA's Jan 2026 rating report · checked

01Where the money goes · FY26

Where does ₹100 of Dr. Reddy's' money go?

Of every ₹100 that came in (revenue plus other income), this is where it went.

Dr. Reddy's · FY26

Receipt for every ₹100

Where ₹100 of Dr. Reddy's' money went in FY26
Materials and goods bought₹34.9
Employees₹17.1
Other running costs (incl. write-downs)₹25.7
Depreciation and amortisation₹5.9
Interest₹1.1
Income tax₹3.5
Kept as profit for shareholders₹12.0
Total₹100

Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.

How this is worked out

Cityfort calculation from the FY26 audited results: each line ÷ ₹35,110 crore that came in (revenue ₹33,700 crore, other income ₹1,358 crore, and ₹52 crore from associates and minority partners' share of losses). Other running costs include ₹352 crore of write-downs. ₹12.0 was kept as profit; rounded lines add to 100.2.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report results, explained in 5 points.

We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.

We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.

02The business in one line

What does Dr. Reddy's do?

Drug wholesalers, pharmacies, hospitals and other drug makers pay Dr. Reddy's for medicines and ingredients; materials take ₹34.9 of every ₹100, and ₹12.0 is profit.

  • Customers in the US paid 35.1% of FY26 revenue, down from 45.9% in FY25, after US lenalidomide exclusivity ended in Jan 2026.
  • Profit for shareholders fell 25.8% in FY26, to ₹4,196 crore, and fell 50.5% in H1 FY27 from a year earlier.

03Who pays it

Who pays Dr. Reddy's?

  • Buyers of finished medicines

    88.9%

    of revenue

    Wholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue.

  • Other drug makers

    10.5%

    of revenue

    Buy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business.

  • Others

    0.6%

    of revenue

    Aurigene Oncology (a drug discovery business) and proprietary products.

  • Buyers of finished medicines88.9%
  • Other drug makers10.5%
  • Others0.6%

How spread out the customers are

The Indian filings do not disclose revenue by customer. The FY26 BRSR lists customer types only.

04How it makes money

How does Dr. Reddy's make money?

Profit has followed US generics: it fell after US lenalidomide exclusivity ended in Jan 2026.

ICRA's Jan 2026 report lists price competition in US generics as a challenge. After US lenalidomide exclusivity ended in Jan 2026, North America revenue fell 22% in FY26 (company figures). Dr. Reddy's kept ₹19.9 of profit per ₹100 of revenue in FY24 and ₹12.5 in FY26.

Profit for shareholders per ₹100 of revenue

₹19.9₹12.5

FY24 to FY26

  1. Dr. Reddy's files to sell copies of medicines whose patents are ending (77 US applications pending, Sep 2026).
  2. Its own ingredient plants supply many of the active ingredients.
  3. An early approval can mean few rival sellers for a while.
  4. Rivals arrive and prices fall, as with lenalidomide after Jan 2026.
  5. Profits pay for R&D, 7.2% of FY26 revenue by the company's count, and the next filings.
  6. Branded businesses (India, emerging markets and nicotine gums) were 53% of Q2 FY27 revenue (company figure).

↺ Step 6 feeds back into step 1.

05Business segments · FY26

Which businesses make up Dr. Reddy's?

  • Global Generics

    88.9%

    Finished medicines in North America, Europe, India and emerging markets, including biosimilars and nicotine gums. FY26 gross profit was ₹16,970 crore of the company's ₹17,728 crore.

    Revenue ₹29,946 cr

  • Pharmaceutical Services and Active Ingredients (PSAI)

    10.5%

    Active ingredients and contract services for other drug makers, shown after ₹727 crore of sales to Global Generics. FY26 gross profit was ₹600 crore.

    Revenue ₹3,540 cr

  • Others

    0.6%

    Aurigene Oncology (drug discovery) and proprietary products. FY26 gross profit was ₹158 crore.

    Revenue ₹214 cr

How the mix changed

  • Global Generics
  • Pharmaceutical Services and Active Ingredients (PSAI)
  • Others

Revenue by segment, FY25 to FY26.

₹ crore

See the numbers
How the mix changed (₹ crore)
YearGlobal GenericsPharmaceutical Services and Active Ingredients (PSAI)Others
FY25₹28,981₹3,448₹215
FY26₹29,946₹3,540₹214

06The numbers · Consolidated · ₹ crore

How has Dr. Reddy's done?

Revenue

₹33,700 crFY26

Revenue rose every year from ₹21,545 crore in FY22 to ₹33,700 crore in FY26; Q2 FY27 revenue of ₹8,698 crore was 1.5% below Q2 FY26.

₹ crore

See the numbers
Revenue (₹ crore)
PeriodRevenue (₹ cr)
FY22₹21,545
FY23₹24,670
FY24₹28,011
FY25₹32,644
FY26₹33,700
Q3 FY25₹8,381
Q4 FY25₹8,528
Q1 FY26₹8,572
Q2 FY26₹8,828
Q3 FY26₹8,753
Q4 FY26₹7,546
Q1 FY27₹8,100
Q2 FY27₹8,698

Net profit

₹4,196 crFY26

Q4 FY26 profit of ₹221 crore carried a ₹453 crore lenalidomide shelf-stock adjustment and write-downs, and Q1 FY27 (₹444 crore) a ₹239.7 crore semaglutide provision.

₹ crore

See the numbers
Net profit (₹ crore)
PeriodNet profit (₹ cr)EPS (₹)
FY22₹2,183₹26.24
FY23₹4,507₹54.18
FY24₹5,578₹66.92
FY25₹5,655₹67.79
FY26₹4,196₹50.35
Q3 FY25₹1,414₹16.94
Q4 FY25₹1,593₹19.10
Q1 FY26₹1,418₹17.02
Q2 FY26₹1,347₹16.17
Q3 FY26₹1,210₹14.52
Q4 FY26₹221₹2.65
Q1 FY27₹444₹5.33
Q2 FY27₹925₹11.09

Net profit for every ₹100 of revenue

₹12.5FY26

Dr. Reddy's kept ₹10.1 of profit per ₹100 of revenue in FY22, ₹19.9 in FY24 and ₹12.5 in FY26; FY26 EBITDA margin was 19.1% by Cityfort's calculation and 22.8% by the company's own IFRS figure.

Net margin: ₹ of net profit per ₹100 of revenue

See the numbers
Net profit for every ₹100 of revenue (Net margin: ₹ of net profit per ₹100 of revenue)
YearNet marginEBITDA margin
FY2210.1%17.5%
FY2318.3%25.7%
FY2419.9%28.3%
FY2517.3%26.2%
FY2612.5%19.1%

Free cash flow

₹1,833 crFY26

Free cash flow was ₹1,833 crore in FY26 and −₹367 crore in H1 FY27, when a USD 50 million lenalidomide claim was paid, the CFO said.

₹ crore · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (₹ crore · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY22₹2,811₹1,905₹906
FY23₹5,887₹1,886₹4,001
FY24₹4,543₹2,744₹1,800
FY25₹4,643₹3,440₹1,203
FY26₹5,674₹3,841₹1,833
See all yearly numbers
Dr. Reddy's annual financials, FY22–FY26, ₹ crore
YearRevenueEBITDANet profitEPS (₹)Net income, total (₹ cr)Operating cashCapexFree cash
FY22₹21,545₹3,768₹2,183₹26.24–₹2,811₹1,905₹906
FY23₹24,670₹6,349₹4,507₹54.18–₹5,887₹1,886₹4,001
FY24₹28,011₹7,933₹5,578₹66.92–₹4,543₹2,744₹1,800
FY25₹32,644₹8,547₹5,655₹67.79₹5,725₹4,643₹3,440₹1,203
FY26₹33,700₹6,454₹4,196₹50.35₹4,158₹5,674₹3,841₹1,833

EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners. Total net income differs from net profit to the company's owners: Minority partners bore ₹38 crore of losses, so profit for Dr. Reddy's shareholders is above total profit.

07Who runs it

Who runs Dr. Reddy's, and did they deliver?

  • K Satish Reddy

    Chairman & Whole-time Director · since 2014

    Part of the promoter group. Managing Director from 1997 and Chairman from 13 May 2014.

  • G V Prasad

    Co-Chairman & Managing Director

    Part of the promoter group. Re-appointed for five years from 30 Jan 2026.

  • Erez Israeli

    Chief Executive Officer

  • M V Narasimham

    Chief Financial Officer

  • Akhil Ravi

    Head, API and Services · since 2026

    Appointed from 13 Nov 2026, after Deepak Sapra resigned as CEO of API and Services.

  • K Randhir Singh

    Company Secretary

What they said, and what happened

1 delivered · 1 withdrawn · 4 too early to tell

  1. Said on 23 Jul 2025

    Appoint Deloitte Haskins & Sells LLP as statutory auditors from FY27, in a mandatory rotation.

    What happened

    Shareholders appointed Deloitte at the AGM on 23 Jul 2026, for five years.

    Delivered
  2. Said on 12 May 2026

    Sell about 10 to 11 million semaglutide pens in FY27, near the 12 million discussed earlier (management, Q4 FY26 call).

    What happened

    On 9 Jul 2026 the company said batches failed specification because of an ingredient issue. On 22 Jul 2026 management spoke of 6 to 7 million pens between November and March.

    Withdrawn
  3. Said on 12 May 2026

    Gross margin to improve and be above 50% in FY27 (management, Q4 FY26 call).

    What happened

    The company's own gross margin figure (IFRS) was 46.5% in Q1 FY27 and 52.1% in Q2 FY27.

    Too early to tell
  4. Said on 12 May 2026

    Keep the EBITDA margin of the business without semaglutide at around 20% (management, Q4 FY26 call; a company IFRS measure).

    What happened

    The company's EBITDA margin was 12.5% in Q1 FY27 (15.4% without semaglutide) and 20.6% in Q2 FY27.

    Too early to tell
  5. Said on 12 May 2026

    Effective tax rate of 24 to 25% for FY27 (management, Q4 FY26 call).

    What happened

    In H1 FY27 tax was 24.2% of profit before tax (Cityfort calculation from the Q1 and Q2 FY27 results).

    Too early to tell
  6. Said on 22 Jul 2026

    Resume semaglutide commercial supplies by November 2026 (management, Q1 FY27 call).

    What happened

    On 23 Oct 2026 management said it expected to re-launch in November 2026, subject to successful validation.

    Too early to tell

08What could go wrong

What could go wrong for Dr. Reddy's?

  • Competition

    Price competition in US generics

    US customers paid 35.1% of FY26 revenue, down from 45.9% in FY25. After lenalidomide exclusivity ended in Jan 2026, North America revenue fell 23% in Q2 FY27 (company figure). ICRA lists US generics price competition as a challenge.

    Watch North America revenue each quarter (₹2,489 crore in Q2 FY27, company figure).

  • Regulation

    US FDA inspection findings

    Plants that supply the US must pass US FDA inspections. As of 11 Nov 2026 the company had disclosed four inspections with Form 483s and one records assessment (Form FDA 2953) with no final classification, including 7 observations at its biologics plant in Jun 2026.

    Watch FDA classification of the open inspections, and any warning letter or import alert.

  • Execution

    Semaglutide supply problem

    On 9 Jul 2026 the company said semaglutide batches failed specification because of an ingredient (API) issue. Q1 FY27 carried a ₹239.7 crore provision for inventory and related costs.

    Watch Whether semaglutide supplies resume, and semaglutide sales in Q3 and Q4 FY27.

  • Legal

    Pending US antitrust lawsuits

    US class actions allege price-fixing of generic medicines, and other suits make antitrust claims over Revlimid (lenalidomide). The company says most amounts cannot be reasonably estimated and has made no provision.

    Watch Court rulings, and any provision in the results notes.

  • Regulation

    Russia taxes and exposure

    Customers in Russia paid 10.4% of FY26 revenue. FY26 included Russian VAT provisions of ₹69.5 crore in Q2 and ₹114.1 crore in Q4.

    Watch Russia revenue (₹1,008 crore in Q2 FY27, company figure) and any new tax provisions.

  • Cash and liquidity

    Weaker cash flow in H1 FY27

    Operating cash flow was ₹435 crore in H1 FY27, against ₹3,020 crore in H1 FY26. After ₹802 crore of capex, free cash flow was −₹367 crore.

    Watch Operating cash flow in the H2 FY27 results.

  • Execution

    Write-downs on research bets

    FY26 included ₹352 crore of write-downs, among them ₹129.1 crore for a stopped CAR-T programme and ₹91.4 crore for eftilagimod alfa, whose Phase III trial was stopped for futility.

    Watch Impairment charges in each quarter's results.

09Supporters and critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year, from ₹21,545 crore in FY22 to ₹33,700 crore in FY26.
  • In Q2 FY27 emerging markets revenue rose 24% and India 17% from a year earlier (company figures).
  • On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore; ICRA rates the company AA+/Stable.
  • No promoter shares were pledged in any of the 12 quarters to Sep 2026.
  • The company says North America revenue excluding lenalidomide rose 29% in Q2 FY27.

What critics point to

  • Profit for shareholders fell 25.8% in FY26, and 50.5% in H1 FY27 from a year earlier.
  • US customers' share of revenue fell from 45.9% in FY25 to 35.1% in FY26.
  • From Jun to Oct 2026, four FDA inspections with Form 483s and one records assessment (Form FDA 2953) ended with observations, not yet classified as of 11 Nov 2026.
  • Semaglutide supplies stopped after batches failed specification; Q1 FY27 carried a ₹239.7 crore provision.
  • Free cash flow was −₹367 crore in H1 FY27.

10What to watch next

What should you watch next at Dr. Reddy's?

Next event

Q3 FY27 results

Date not announced yet.

  • Semaglutide re-launch

    Management said on the Q2 FY27 call (23 Oct 2026) it expected to re-launch semaglutide in November 2026, subject to validation; on 22 Jul 2026 it spoke of 6 to 7 million pens between November and March.

  • US FDA outcomes

    The biologics plant got 7 observations in a Jun 2026 pre-licence inspection, and the abatacept biosimilar awaits US approval.

  • North America after lenalidomide

    North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier (company figure). Q3 FY26 results were filed on 21 Jan 2026.

11Key facts

Key facts about Dr. Reddy's

What does Dr. Reddy's do?
Dr. Reddy's Laboratories, based in Hyderabad, makes generic and branded medicines and their active ingredients. Dr. Reddy's sold in 87 countries in FY26, and its FY26 revenue from operations was ₹33,700 crore.
How does Dr. Reddy's make money?
Dr. Reddy's earns most of its money from finished medicines. Its Global Generics segment was 88.9% of FY26 revenue and earned ₹16,970 crore of Dr. Reddy's ₹17,728 crore gross profit. Active ingredients and services (PSAI) were 10.5% of revenue.
Who are Dr. Reddy's customers?
Dr. Reddy's sells to wholesalers, distributors, pharmacy chains, hospitals, government institutions and other drug makers. In FY26, customers in the US paid 35.1% of Dr. Reddy's revenue, India 19.2% and Russia 10.4%. Dr. Reddy's Indian filings do not disclose revenue by customer.
How big is Dr. Reddy's?
In FY26 Dr. Reddy's consolidated revenue from operations was ₹33,700 crore and its profit for shareholders was ₹4,196 crore. Dr. Reddy's had 27,527 permanent employees and 24 manufacturing facilities in FY26.
Who owns Dr. Reddy's?
On 30 Sep 2026 the promoter group, the families of K Satish Reddy and G V Prasad, held 26.63% of Dr. Reddy's, with no shares pledged. JP Morgan Chase Bank, depository for Dr. Reddy's US-listed ADRs, held 11.10% for ADR holders. Other foreign investors held 20.30%, Indian institutions 31.88% (LIC 12.14%) and individuals and others 9.90%.
Why was Dr. Reddy's FY26 profit lower than FY25?
Dr. Reddy's FY26 profit for shareholders of ₹4,196 crore was 25.8% below FY25's ₹5,655 crore. US lenalidomide exclusivity ended in Jan 2026, and Q4 FY26 revenue carried a ₹453 crore lenalidomide shelf-stock adjustment. FY26 also included ₹352 crore of write-downs (impairments).
Does Dr. Reddy's have debt?
On 30 Sep 2026 Dr. Reddy's had ₹5,826 crore of borrowings and ₹6,874 crore of cash, bank balances and short-term investments. ICRA rated Dr. Reddy's AA+ with a stable outlook on 9 Jan 2026.
What dividend did Dr. Reddy's pay for FY26?
Dr. Reddy's board recommended a final dividend of ₹8 per share for FY26 on 12 May 2026. That was 15.9% of Dr. Reddy's FY26 basic earnings per share of ₹50.41 (Cityfort calculation).
Where are Dr. Reddy's shares listed?
Dr. Reddy's shares trade on the NSE as DRREDDY and on the BSE as 500124. Dr. Reddy's American depositary receipts (ADRs) trade on the New York Stock Exchange as RDY.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

12What it sells

12What it sells

What does Dr. Reddy's sell?

Dr. Reddy's makes medicines and sells them in 87 countries. Most are generics: copies of medicines whose patents have ended. It also sells branded medicines in India and active ingredients to other drug makers.
  • Generic medicines for North America

    Copies of off-patent medicines sold in the US and Canada. The company's figure (IFRS) for FY26 was ₹11,374 crore, down 22% from FY25.

  • Branded medicines in India

    Medicines sold in India under Dr. Reddy's brand names, including Obeda semaglutide from Mar 2026. The company's figure for FY26 was ₹6,219 crore, up 16%.

  • Emerging markets

    Medicines sold in Russia, other CIS countries and the rest of the world. The company's figure for FY26 was ₹6,761 crore, up 23%.

  • Europe, including nicotine gums

    Generics in Germany, the UK and other countries, plus nicotine replacement brands such as Nicotinell bought from Haleon. The company's figure for FY26 was ₹5,550 crore, up 55%.

  • Active ingredients and services (PSAI)

    Active pharmaceutical ingredients (APIs, the chemicals that make a medicine work) and contract services for other drug makers. The company's figure for FY26 was ₹3,477 crore.

  • Biosimilars and partner products

    Biosimilars are near-copies of medicines made from living cells. An abatacept biosimilar awaits US approval. On 18 Sep 2026 Dr. Reddy's signed an agreement to distribute Takeda's dengue vaccine Qdenga in India's private market, with launch planned for H1 2027.

Think of it like this

A generic medicine is like a copy of a book whose copyright has ended: any approved printer may print it.

What it does

  • Does: Makes generic copies of off-patent medicines for the US, Europe, Russia and other markets
  • Does: Sells branded medicines in India
  • Does: Makes active ingredients for its own medicines and for other drug makers
  • Does: Develops biosimilars, and signed an agreement (18 Sep 2026) to distribute Takeda's Qdenga vaccine in India's private market from H1 2027

What it does not do

  • Does not: Report in only one set of accounts: it files Ind AS results (used on this page) and IFRS results
  • Does not: Have any promoter shares pledged: none in the 12 quarters to Sep 2026
  • Does not: Disclose revenue by customer in its Indian filings
  • Does not: Sell Novartis India brands any more: that distribution deal ended, with sales until 30 Sep 2026
13How the money flows

13How the money flows · FY26

How does money flow through Dr. Reddy's?

Money in

  • Revenue from operations₹33,700 cr
  • Share of associates' profit and of losses borne by minority partners₹52 cr
  • Other income₹1,358 cr

The company

Dr. Reddy's

₹35,110 cr came in

Money out

  • Materials and goods bought₹12,239 cr
  • Employee costs₹5,991 cr
  • Other running costs (incl. ₹352 crore of write-downs)₹9,017 cr
  • Depreciation and amortisation₹2,059 cr
  • Interest₹374 cr
  • Income tax₹1,235 cr
  • Net profit for Dr. Reddy's shareholders₹4,196 cr
  1. In FY26 Dr. Reddy's sold ₹33,700 crore of medicines, ingredients and services, and had ₹1,358 crore of other income.
  2. Materials and goods bought took ₹12,239 crore, and employees ₹5,991 crore.
  3. Other running costs took ₹9,017 crore, including ₹352 crore of write-downs (impairments).
  4. Depreciation took ₹2,059 crore, interest ₹374 crore and income tax ₹1,235 crore.
  5. What was left for Dr. Reddy's shareholders was ₹4,196 crore of profit.
14What it needs to run

14What it needs to run

What does Dr. Reddy's need to run?

  • Factories

    24 manufacturing facilities in FY26, according to the annual report. Plants that supply the US must pass US FDA inspections.

  • US product applications

    77 generic applications (ANDAs) and 3 new-drug applications were pending with the US FDA in Sep 2026, including 47 patent challenges (Para IV) and 27 first-to-file.

  • Research

    The company says R&D spending was 7.2% of FY26 revenue, down 12%, after most of its abatacept biosimilar investment was completed.

  • Own ingredient plants

    The PSAI segment sold ₹727 crore of ingredients to Dr. Reddy's own generics business in FY26. ICRA says this backward integration gives a cost advantage.

  • People

    27,527 permanent employees and 9,199 other workers in FY26, according to the BRSR.

15Where it sells

15Where it sells · FY26

Where does Dr. Reddy's sell?

  • United States35.1%
  • India19.2%
  • Russia10.4%
  • Other countries35.3%
16Competitors and what protects it

16Competitors and what protects it

Who does Dr. Reddy's compete with?

Dr. Reddy's own filings do not name competitors. Citing IQVIA, it says it ranked 8th in India's medicine market in the quarter to Sep 2026. Sun Pharma's Sep 2026 presentation (AIOCD data) puts Dr. Reddy's AIOCD-tracked formulation sales at ₹7,956 crore, a 3.1% share, in the 12 months to Jun 2026.
  • Sun Pharmaceutical Industries

    NSE: SUNPHARMA

    Ranked first in India's medicine market: ₹21,538 crore of India sales, an 8.5% share, in the 12 months to Jun 2026 (AIOCD data in its own presentation).

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • Own ingredient supply4 of 5

    The PSAI segment makes active ingredients and sold ₹727 crore of them to Dr. Reddy's own generics business in FY26. ICRA (Jan 2026) says this backward integration gives a significant cost advantage.

  • Spread across markets4 of 5

    In FY26 customers in the US paid 35.1% of revenue, India 19.2%, Russia 10.4% and other countries 35.3%. It sold in 87 countries.

  • US filings pipeline3 of 5

    77 generic and 3 new-drug applications were pending with the US FDA in Sep 2026, including 27 first-to-file.

  • India brands3 of 5

    The company says, citing IQVIA, it ranked 8th in India in the quarter to Sep 2026, and its India sales grew 21.0% against the market's 14.7%.

  • Cash and borrowings4 of 5

    On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore (Cityfort calculation). ICRA rated it AA+/Stable on 9 Jan 2026.

Weak spot

Reliance on US generics

US customers' share of revenue fell from 45.9% in FY25 to 35.1% in FY26 after lenalidomide exclusivity ended in Jan 2026. North America revenue fell 23% in Q2 FY27 (company figure).

17Where growth could come from

17Where growth could come from

Where could Dr. Reddy's' growth come from?

Management said on the Q2 FY27 call (23 Oct 2026) that it expected to re-launch semaglutide in November 2026, "subject to successful validation". CFO M V Narasimham said the company wants gross margin of 50 to 55% (a company IFRS measure).
Management statement, 23 Oct 2026. Reported as a statement, not our forecast.
  • Semaglutide (diabetes and weight-loss injection)

    Behind

    ₹239.7 crore provision, Q1 FY27

    Launched in India in Mar 2026 and Canada in May 2026. On 9 Jul 2026 the company said batches failed specification because of an ingredient issue. It said on 5 Nov 2026 that Brazil had granted marketing authorisation.

    Status: Behind, behind the company's own plan.

  • India

    Working

    +17% YoY, Q2 FY27 (company figure)

    India revenue was ₹1,851 crore in Q2 FY27. Citing IQVIA, the company says its India sales grew 21.0% against the market's 14.7%.

    Status: Working, on track against what the company said.

  • Emerging markets

    Working

    +24% YoY, Q2 FY27 (company figure)

    Emerging markets revenue was ₹2,059 crore in Q2 FY27, including ₹1,008 crore from Russia. In FY26 it rose 23%.

    Status: Working, on track against what the company said.

  • North America without lenalidomide

    Mixed

    ₹2,489 crore, −23% YoY, Q2 FY27

    North America revenue fell 23% in Q2 FY27. The company says it rose 29% excluding lenalidomide.

    Status: Mixed, partly on track.

  • Europe and nicotine gums

    Mixed

    +1% YoY, Q2 FY27 (company figure)

    Europe revenue rose 55% in FY26; the nicotine replacement business bought from Haleon is included from Q3 FY25. In Q2 FY27 Europe revenue was ₹1,393 crore, up 1%.

    Status: Mixed, partly on track.

  • Abatacept biosimilar

    Early

    US approval awaited

    Management said on 23 Oct 2026 that abatacept sales should reach hundreds of millions of dollars. The biologics plant got 7 observations in a Jun 2026 FDA pre-licence inspection.

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

18Financial strength and debt

18Financial strength · 30 Sep 2026

How much debt does Dr. Reddy's have?

On 30 Sep 2026 Dr. Reddy's cash and short-term investments were ₹1,048 crore more than its borrowings (Cityfort calculation from the Q2 FY27 results).
  • Total debt₹5,826 cr
  • Cash and investments₹6,874 cr
  • Net cash (cash minus debt)₹1,048 cr
  • Net worth (shareholders' money)₹38,807 cr
Debt to equity
0.15×
₹ of debt for every ₹1 of shareholders' money
Interest cover
8.1×
how many times operating profit covers interest
  • Cash and short-term investments = cash, other bank balances and current investments. All borrowings were short-term.
  • Lease liabilities (rent owed under leases) were a further ₹1,403 crore; counting them, debt exceeded cash by ₹355 crore (Cityfort calculation).
  • The company reports a "net cash surplus" of ₹2,502 crore on its own IFRS definition, which adjusts for non-current cash and borrowings.
  • Borrowings rose from ₹1,652 crore on 31 Mar 2024 to ₹4,185 crore a year later, the year it bought the nicotine replacement business from Haleon.
  • Interest cover = (profit before tax + interest) ÷ interest, H1 FY27 (Cityfort calculation). Debt to equity = borrowings ÷ total equity.
19Who owns it

19Who owns it · Q2 FY27

Who owns Dr. Reddy's?

  • Promoters (founders or parent company)26.6%
  • Foreign institutions (FII)20.3%
  • Indian institutions (DII)31.9%
  • Public and others21.0%

Promoter pledge

No promoter shares were pledged in Q2 FY27.

How ownership changed
Dr. Reddy's shareholding by quarter, %
QuarterPromotersFIIDIIPublicOthers†Pledged*
Q3 FY2426.7%28.6%18.7%10.6%15.3%0.0%
Q4 FY2426.7%29.1%18.3%10.4%15.4%0.0%
Q1 FY2526.7%27.7%20.7%10.2%14.6%0.0%
Q2 FY2526.6%27.5%21.5%10.0%14.2%0.0%
Q3 FY2526.6%26.9%22.9%10.2%13.2%0.0%
Q4 FY2526.6%25.8%25.6%10.2%11.5%0.0%
Q1 FY2626.6%25.3%26.7%10.0%11.0%0.0%
Q2 FY2626.6%24.7%28.0%9.6%10.8%0.0%
Q3 FY2626.6%22.3%30.4%9.5%10.9%0.0%
Q4 FY2626.6%21.1%30.7%9.3%11.9%0.0%
Q1 FY2726.6%20.7%31.7%9.4%11.4%0.0%
Q2 FY2726.6%20.3%31.9%9.9%11.1%0.0%

* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.

† Others = Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions).

20What it does with profit

20What it does with profit

What does Dr. Reddy's do with its profit?

Dividends per share are on ₹1 shares, as the FY26 annual report states them. FY22–FY24 were declared as ₹30, ₹40 and ₹40 on ₹5 shares, before the 1:5 split of 28 Oct 2024. Payout = dividend ÷ basic earnings per share (Cityfort calculation). FY22–FY24 earnings per share are divided by 5 for the split, as in the EPS column. There were no buybacks or fund raises from FY22 to Sep 2026, only employee stock option allotments.

Dividend per share

₹8.00FY26

Dividend paid for each share, by financial year.

₹ per share

See the numbers
Dividend per share (₹ per share)
YearDividend per shareShare of profit paid out
FY22₹6.0022.8%
FY23₹8.0014.7%
FY24₹8.0011.9%
FY25₹8.0011.8%
FY26₹8.0015.9%

No buybacks or fund raises in the period covered.

21Governance signals

21Governance signals

What do Dr. Reddy's' governance filings show?

Auditor
Deloitte Haskins & Sells LLP, since 2026
Auditor changes
23 Jul 2026: S.R. Batliboi & Associates LLP → Deloitte Haskins & Sells LLP (Mandatory rotation, the company said. Shareholders appointed Deloitte at the 42nd AGM for five years, to the 47th AGM. S.R. Batliboi audited FY22–FY26.)
Audit qualifications
None reported
Related-party dealings
In FY26 Dr. Reddy's gave ₹74.4 crore of CSR money to Dr. Reddy's Foundation and paid Green Park Hospitality ₹49.0 crore for catering. It paid Indus Projects ₹26.2 crore for civil works and K Satish Reddy ₹1.9 crore in rent. Pay to key managers totalled ₹147.9 crore.
Credit rating
ICRA [ICRA]AA+ (long-term bank limits, ₹2,000 crore) (outlook Stable), 9 Jan 2026

A credit rating describes the company's ability to repay debt. It is not a rating of the share.

Flags to know about

  • regulatory · 14 Oct 2026

    US FDA inspections awaiting classification

    A Form 483 lists issues FDA inspectors observed. As of 11 Nov 2026, four inspections with Form 483s and one records assessment (Form FDA 2953) had no disclosed final classification: biologics, Bachupally (7 observations, Jun 2026); FTO-3, Bachupally (4, Aug 2026); API, Mexico (Form FDA 2953, 2, Sep 2026); FTO-11 (2) and FTO-9 (3), Oct 2026.

  • regulatory · 28 Oct 2026

    Recent FDA inspections closed

    The company disclosed VAI (voluntary action indicated) results for API Mirfield, UK (14 Aug 2026) and FTO-SEZ Process Unit-02, Srikakulam (28 Oct 2026). ICRA noted no warning letters, import alerts or OAI classifications in recent inspections (Jan 2026).

  • regulatory · 5 Mar 2026

    US FCPA inquiries closed

    After an anonymous complaint in Sep 2020 about Ukraine and other markets, the US SEC said on 23 Feb 2026 it does not intend to recommend enforcement action. The US Department of Justice closed its inquiry on 5 Mar 2026, the company disclosed.

  • other · 30 Jun 2026

    US antitrust lawsuits pending

    Dr. Reddy's is a defendant in US class actions alleging price-fixing of generic medicines, and in Revlimid (lenalidomide) antitrust suits, where motions to dismiss were pending. The company says most amounts cannot be reasonably estimated and has made no provision.

  • regulatory · 3 Oct 2026

    Small tax penalties abroad

    A Russian subsidiary's tax penalty of RUB 9.27 million (₹1.14 crore) became final on 13 Apr 2026; the company said it has no material impact. The IRS levied a USD 32,350 penalty on the US subsidiary in Oct 2026.

  • disclosure · 12 May 2026

    Two sets of accounts

    The company files Ind AS results in India and IFRS results for its US listing. FY26 profit for shareholders was ₹4,196 crore under Ind AS and ₹4,285 crore under IFRS. This page uses Ind AS.

  • other · 17 Sep 2025

    Promoter shares moved to family trusts

    On 17 Sep 2025 K Satish Reddy moved 9.06% to the VSD Family Trust and G V Prasad 11.51% to the GVP Family Trust. The promoter group's total holding did not change.

22What the market paid

22What the market paid · price as of 11 Nov 2026

What did the market pay for Dr. Reddy's on 11 Nov 2026?

Price as of 11 Nov 2026 (shown for education; prices change daily).

Price as of 11 Nov 2026: ₹1,377.00, the NSE closing price. Market value = price × 834,680,285 shares (Sep 2026 shareholding filing) = ₹114,935 crore. P/E (market value per rupee of yearly profit) = market value ÷ profit of the last four quarters (Q3 FY26 to Q2 FY27, ₹2,799.9 crore) = 41.0; those quarters include the Q4 FY26 and Q1 FY27 one-off charges. On FY26 diluted earnings per share of ₹50.35 the P/E is 27.3. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹38,807 crore) = 3.0. Dividend yield = FY26 dividend of ₹8 ÷ price = 0.58%. All are Cityfort calculations from the NSE bhavcopy and the company's filings.

Share price
₹1,377.00
Market value (market cap)
₹114,935 cr
P/E
41×
P/B
3×

Source: NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close); Shareholding pattern as of Sep 2026 (NSE XBRL); Q3 FY26 consolidated financial results (Ind AS, NSE XBRL) and 4 more

23How it got here

23How it got here

How did Dr. Reddy's get here?

  1. 1984

    Milestone

    Incorporated

    Dr. Reddy's was incorporated in 1984 and made its first public share issue on 9 Aug 1986, according to its FY26 annual report. Its registered office is in Hyderabad.

  2. 2001

    Milestone

    Listed in New York

    Its ADRs began trading on the New York Stock Exchange on 11 Apr 2001. Cheminor Drugs merged into the company in Jan 2001.

  3. 2022

    Milestone

    Promoter holding company merged in

    The NCLT approved the merger of Dr. Reddy's Holdings, the promoters' holding company, into Dr. Reddy's on 5 Apr 2022. The promoters indemnify the company for a tax reassessment of that merger.

  4. 2024

    Business-model change

    Bought nicotine replacement brands

    It bought Haleon's nicotine replacement portfolio, including Nicotinell, consolidated from Q3 FY25. Europe revenue rose 55% in FY26 (company figure).

  5. 2024

    Milestone

    Shares split 1:5

    Each ₹5 share became five ₹1 shares from 28 Oct 2024.

  6. 2025

    Milestone

    Promoter shares moved to family trusts

    On 17 Sep 2025 the two promoters moved 20.58% of the company to two family trusts; the promoter total did not change.

  7. 2026

    Crisis

    US lenalidomide exclusivity ended

    Exclusivity ended in Jan 2026. Q4 FY26 revenue carried a ₹453 crore shelf-stock adjustment, and North America revenue fell 22% in FY26 (company figure).

  8. 2026

    Crisis

    Semaglutide launched, then paused

    Launched in India on 21 Mar 2026 and Canada on 15 May 2026. On 9 Jul 2026 batches failed specification, and supplies were delayed.

  9. 2026

    Milestone

    New auditor

    Deloitte Haskins & Sells LLP replaced S.R. Batliboi & Associates as statutory auditor at the 23 Jul 2026 AGM, a mandatory rotation.

24Sources and changes

Where every number on this page comes from

Sources (60 documents)
  1. S1Integrated Annual Report FY2025-26 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Jun 2026
  2. S2Business Responsibility and Sustainability Report FY2025-26 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Jun 2026
  3. S3Q2 FY27 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 23 Oct 2026
  4. S4Q2 FY27 results filing: board outcome and financial results (PDF) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
  5. S5Q2 FY27 results presentation (IFRS) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
  6. S6Q2 FY27 earnings call transcript (23 Oct 2026) · Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026) · Tier 1: company or exchange filing · 29 Oct 2026
  7. S7Q1 FY27 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 22 Jul 2026
  8. S8Q1 FY27 results filing (PDF, notes) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 22 Jul 2026
  9. S10Q1 FY27 earnings call transcript (22 Jul 2026) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 28 Jul 2026
  10. S11Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 12 May 2026
  11. S12Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 12 May 2026
  12. S13Q4 FY26 earnings call transcript (12 May 2026) · Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 18 May 2026) · Tier 1: company or exchange filing · 18 May 2026
  13. S14Q3 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jan 2026
  14. S17Q2 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 24 Oct 2025
  15. S18Q1 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 23 Jul 2025
  16. S19Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 9 May 2025
  17. S20Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 9 May 2025
  18. S21Q3 FY25 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 24 Jan 2025
  19. S22Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 7 May 2024
  20. S23Q4 FY24 results filing (PDF; FY23 comparatives) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 7 May 2024
  21. S24Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 10 May 2023
  22. S25Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 May 2022
  23. S26Shareholding pattern as of Dec 2023 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jan 2024
  24. S27Shareholding pattern as of Mar 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Apr 2024
  25. S28Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jul 2024
  26. S29Shareholding pattern as of Sep 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2024
  27. S30Shareholding pattern as of Dec 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jan 2025
  28. S31Shareholding pattern as of Mar 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Apr 2025
  29. S32Shareholding pattern as of Jun 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2025
  30. S33Shareholding pattern as of Sep 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 16 Oct 2025
  31. S34Shareholding pattern as of Dec 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 20 Jan 2026
  32. S35Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2026
  33. S36Shareholding pattern as of Jun 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2026
  34. S37Shareholding pattern as of Sep 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2026
  35. S38ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable) · ICRA Ltd · Tier 2: rating agency or regulator · 9 Jan 2026
  36. S40NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
  37. S41Intimation: semaglutide batches out of specification due to API issue; supplies delayed · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 9 Jul 2026
  38. S42Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Sep 2025
  39. S43Disclosure: US SEC concludes FCPA investigation, no enforcement recommended · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 24 Feb 2026
  40. S44Disclosure: US DOJ closes FCPA inquiry · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 6 Mar 2026
  41. S45Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Jul 2025
  42. S46AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Jul 2026
  43. S48Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 25 Jun 2026
  44. S49Intimation: US FDA classifies API Mirfield (UK) inspection as VAI · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Aug 2026
  45. S51Intimation: US FDA classifies FTO-SEZ Process Unit-02 inspection as VAI · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 28 Oct 2026
  46. S52Intimation: US FDA GMP inspection at formulations facility FTO-3, Bachupally: Form 483 with 4 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Aug 2026
  47. S53Intimation: US FDA records assessment at API facility, Mexico: Form FDA 2953 with 2 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 11 Sep 2026
  48. S54Intimation: US FDA PAI at FTO-11, Pydibhimavaram: Form 483 with 2 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 8 Oct 2026
  49. S55Intimation: resignation of Deepak Sapra, CEO API and Services · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 Aug 2026
  50. S56Intimation: appointment of Akhil Ravi as Head API and Services · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
  51. S57Intimation: US FDA PAI at FTO-9, Visakhapatnam: Form 483 with 3 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Oct 2026
  52. S59Intimation: final tax penalty decision for Russian subsidiary · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Apr 2026
  53. S60Intimation: IRS penalty on US subsidiary Dr. Reddy's Laboratories, Inc. · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 3 Oct 2026
  54. S62Disclosure: Immutep update on TACTI-004 Phase III (eftilagimod alfa) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 Mar 2026
  55. S64Press release: launch of semaglutide injection (Obeda) in India · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 21 Mar 2026
  56. S67Press release: launch of generic semaglutide injection in Canada · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 16 May 2026
  57. S69Disclosure: exclusive distribution agreement with Takeda for Qdenga (India private market) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Sep 2026
  58. S70Press release: marketing authorization for generic semaglutide injection in Brazil · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 5 Nov 2026
  59. S71AGM 24 Jul 2025 outcome: re-appointment of G V Prasad as Co-Chairman and MD · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 24 Jul 2025
  60. S72Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 Sep 2026
Changes to this page (v2 · 17 Nov 2026)
  1. v2 · 17 Nov 2026Reworded the margin caption so it names the company (no numbers changed). (editorial update, Q2 FY27)
  2. v1 · 11 Nov 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.